<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="utf-8">
    <meta http-equiv="X-UA-Compatible" content="IE=edge">
    <meta content="width=device-width, initial-scale=1, maximum-scale=1, user-scalable=no" name="viewport">
    <meta name="description" content="نظام معلومات الأدوية السعودي Saudi Drugs Information System">
    <meta name="author" content="Saudi Food & Drug Authority (SFDA)">
    <noscript><meta http-equiv="refresh" content="0; url=/noScript.html" /></noscript>
    <link rel="shortcut icon" href="/favicon.ico">
    <title>&#x646;&#x638;&#x627;&#x645; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</title>
    <link href="/fonts/roboto/roboto.css?v=53F8z0aw8DRnG9ou9x1tuKMPbNjRZWM-VBHl3B0s9-o" rel="stylesheet" />
    <link href="/fonts/material-icons/materialicons.css?v=8pEJ8MWsFzHRDLY0NI5rssf6T6vankxrJDPnnZxOGrg" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-rtl.css?v=0env-Atj9mTPLILmJGwuDlLIOS_Akxxy4gnH1UUtrjU" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-glyphicons.css?v=U5a39oen_WYzVAAexH5aoahbpqlKHcIzQrnXujf1yio" rel="stylesheet" />
    <link href="/lib/bootstrap-select/dist/css/bootstrap-select.css?v=DeY2lH0e0tmNnO9XZ-gGVOGk6_YoWlZ49y7CnD3ST00" rel="stylesheet" />
    <link href="/lib/toastr/toastr.css?v=kKePN_CyxTiMEgsSDu_7z21ru07YOZtR-0UV0JOkt5o" rel="stylesheet" />
    <link href="/lib/famfamfam-flags/dist/sprite/famfamfam-flags.css?v=JVJiF3s2_kk99xQHfYhfxo_-Dd52ZIruDMOILwPkqv0" rel="stylesheet" />
    <link href="/lib/font-awesome/css/font-awesome.css?v=YIHlqxkiJtENTMuzIHC9EfZaB5RniGr7kF7juUQJUuc" rel="stylesheet" />
    <link href="/lib/Waves/dist/waves.css?v=nd3hxjNg6DhkuFIz5IbxLK8Xw2ac0blsDQpF4pkJxUc" rel="stylesheet" />
    <link href="/lib/animate.css/animate.css?v=IT6GQizZpVcaM1_L_mIiNAYVvZErMgfwewf1GGWXG_I" rel="stylesheet" />
    <link href="/css/materialize.css?v=ey-J3xahkqficOYUHVX3jexmzvRFrge9bmux4CQr1DQ" rel="stylesheet" />
    <link href="/css/Publicstyle.css?v=xhOiVjq-54ODzSIeHXoascHsEJm_n_bIHqZatpxnYhg" rel="stylesheet">
    <link href="/css/Comman.css?v=bcS6_IRqBsBcY1mS_iriWWanrYR0Scdo1ffk8rQGXwQ" rel="stylesheet" />
    <link href="/css/themes/all-themes.css?v=eGSl5zNTWrXYfUx_EJW9ksC3CUTUUxvxmPiA3aQDtQo" rel="stylesheet" />
    <link href="/view-resources/Views/Shared/_Layout.css?v=BLxBuNISlF2O5EBHWdsX039NvnIHy-GtcqeI_MbyIc0" rel="stylesheet" />
    <link href="/lib/enjoyhint/enjoyhint.css?v=rSxIyBbiAvx_48ZcFxbn2DNPCCgEc0FXa2Vb72enxk4" rel="stylesheet" />
    <link href="/lib/dropzone/dropzone.css?v=IQDlHJdeYZ4gMH87EuB1yEG7ujA7DSEkV_SWfACk8Rg" rel="stylesheet" />

    <!-- View specific styles -->
    
    <script type="text/javascript" nonce="c7f26c8w">
        // This is used to get the application's root path from javascript. It's useful if you're running application in a virtual directory under IIS.
        var abp = abp || {};
        abp.appPath = '/';

    </script>
    <style>
        .popover .popover-title {
            text-align: right;
            font-weight: bold;
        }
        .popover .popover-content {
            text-align: right;
            font-size: 14px;
            font-family: 'Almarai', sans-serif;
            color: black;
        }
       
    </style>
</head>
<body>
    <!-- Page Loader -->
    <div class="page-loader-wrapper">
        <div class="loader">
            <div class="preloader">
                <div class="spinner-layer pl-blue">
                    <div class="circle-clipper left">
                        <div class="circle"></div>
                    </div>
                    <div class="circle-clipper right">
                        <div class="circle"></div>
                    </div>
                </div>
            </div>
            <p>&#x628;&#x631;&#x62C;&#x627;&#x621; &#x627;&#x644;&#x625;&#x646;&#x62A;&#x638;&#x627;&#x631; ...</p>
        </div>
    </div>
    <!-- #END# Page Loader -->
    <!-- Overlay For Sidebars -->
    <div class="overlay"></div>
    <!-- #END# Overlay For Sidebars -->
    <!-- Search Bar -->
    <!-- Top Bar -->
    <nav class="navbar navbar-inverse naav" style="margin-bottom: 0;">
        <div class="container-fluid">
            <div class="navbar-header">
                <button type="button" class="navbar-toggle" data-toggle="collapse" data-target="#myNavbar">
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                </button>
            </div>
            <div class="collapse navbar-collapse rtl" id="navbar-collapse">
                <ul class="nav navbar-nav navbar-right">
                    <li><a href="/home/DrugSearch">&#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</a></li>
                        <li><a href="/Account/Login"><i class="fa fa-key"></i>&nbsp;&#x62A;&#x633;&#x62C;&#x64A;&#x644; &#x627;&#x644;&#x62F;&#x62E;&#x648;&#x644;</a></li>
                </ul>
                <ul class="nav navbar-nav navbar-left">
                    <li class="dropdown">
    <a href="javascript:void(0);" class="dropdown-toggle" data-toggle="dropdown" role="button">
        <i class="famfamfam-flags sa" title="&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;"></i>
        <span>&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</span>
        <b class="caret"></b>
    </a>
    <ul class="dropdown-menu pull-right">
                <li><a href="/AbpLocalization/ChangeCulture?cultureName=en"><i class="famfamfam-flags gb"></i> English</a></li>

    </ul>
</li>

                </ul>
            </div>
        </div>
    </nav>
    <section id="mainContent" class="content">
        <nav class="navbar naav" style="margin-bottom: 0;">
            <div class="container-fluid">
                <ul class="nav navbar-nav">
                    <li>
                        <a class="text-center" href="/">
                            <img src="/images/logo_sdi.png" style="margin: auto;" width="250">
                        </a>
                    </li>
                </ul>
                <div class="navbar-header navbar-toggle2 ">
                    <button type="button" class="navbar-toggle navbar-toggle2" data-toggle="collapse"
                            data-target="#myNavbar2">
                        <span class="icon-bar icon-bar2 "></span>
                        <span class="icon-bar icon-bar2"></span>
                        <span class="icon-bar icon-bar2"></span>
                    </button>
                </div>
                <div class="collapse navbar-collapse " id="myNavbar2">
                    <ul class="nav navbar-nav">
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover" data-placement="bottom" title="" data-content="موقع الكترونى يمكن شركات ووكلاء الادويه من رفع النشرات الممارس الصحى ونشرة معلومات المريض وصورة عبوة الدواء المعتمدة من الهيئة العامة للعذاء والدواء بهدف بناء مرجع وطنى للادوية المسجلة يمكن الرجوع له من قبل الممارس الصحى والمريض كمصدر موثوق للمعلومات الدوائية"
                               data-original-title="&#x645;&#x646; &#x646;&#x62D;&#x646;">
                                &#x645;&#x646; &#x646;&#x62D;&#x646;
                            </a>
                        </li>
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover"
                               data-placement="bottom"
                               title=""
                               data-content="&#x627;&#x630;&#x627; &#x643;&#x627;&#x646; &#x644;&#x62F;&#x64A;&#x643;&#x645; &#x645;&#x644;&#x627;&#x62D;&#x638;&#x627;&#x62A; &#x627;&#x648; &#x627;&#x642;&#x62A;&#x631;&#x627;&#x62D;&#x627;&#x62A; &#x64A;&#x631;&#x62C;&#x649; &#x627;&#x644;&#x62A;&#x648;&#x627;&#x635;&#x644; &#x639;&#x644;&#x649;   SDI@SFDA.GOV.SA"
                               data-original-title="&#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;">
                                &#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;
                            </a>
                        </li>

                    </ul>
                </div>
            </div>
        </nav>
        

<div class="col-xs-12">
    <div class="row text-center">
        <a href="/" class="btn bg-blue btn-lg m-b-10 hover-white">&#x628;&#x62D;&#x62B; &#x62C;&#x62F;&#x64A;&#x62F;</a>
    </div>
</div>
<div class="jumbotron" style="margin-bottom: 0px; background-color: white !important;">
    <h3 class="text-center" style="color: #57aabf; ">Search Results</h3>
    <hr width="20%" style="border-top: 3px solid #54ae90;">

    <br>
    <table class="table s-row">
        <thead style="margin-bottom: 30px !important">
                <tr>
                    <th id="M" style="color:white;">
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x627;&#x644;&#x645;&#x645;&#x627;&#x631;&#x633; &#x627;&#x644;&#x635;&#x62D;&#x64A;</a>
                    </th>
                    <th id="A" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</a>
                    </th>
                    <th id="E" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x627;&#x646;&#x62C;&#x644;&#x64A;&#x632;&#x64A;&#x629;</a>
                    </th>
                    <th id="f" class="active-tab" type='button'>
                        <a href="javascript:void(0)" style="color: white;">&#x635;&#x648;&#x631; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>
                    <th id="D" style="color:white; background-color: #47a4ba;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x628;&#x64A;&#x627;&#x646;&#x627;&#x62A; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>

                </tr>
        </thead>
    </table>
    <div id="D-div" class="box-data" style="display: block;">
        <div class="row">

<div class="modal-body rtl">
    <div class="tab-content">
        <div role="tabpanel" class="tab-pane m-r-60  animated fadeIn active" id="edit-user-details">
<div class="row clearfix">
                    <div class="col-lg-6 col-md-6 col-sm-6">
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="RegisterNumber">&#x631;&#x642;&#x645; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        2210234368
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="RegisterYear">&#x633;&#x646;&#x629; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        2023
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="TradeName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x62A;&#x62C;&#x627;&#x631;&#x64A;</label>
                                    <div class="form-line">
                                        Daroxime
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="ScientificName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x639;&#x644;&#x645;&#x64A;</label>
                                    <div class="form-line">
                                        CEFUROXIME AXETIL
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label " for="Strength">&#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        500
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="StrengthUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        mg
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="AdministrationRouteName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x625;&#x633;&#x62A;&#x639;&#x645;&#x627;&#x644;</label>
                                    <div class="form-line">
                                        Oral use
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PharmaceuticalFormName">&#x627;&#x644;&#x634;&#x643;&#x644; &#x627;&#x644;&#x635;&#x64A;&#x62F;&#x644;&#x627;&#x646;&#x64A;</label>
                                    <div class="form-line">
                                        Film-coated tablet
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Size">&#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="SizeUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageSize">&#x62D;&#x62C;&#x645; &#x627;&#x644;&#x639;&#x628;&#x648;&#x629;</label>
                                    <div class="form-line">
                                        14
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageTypeName">&#x627;&#x646;&#x648;&#x627;&#x639; &#x627;&#x644;&#x639;&#x628;&#x648;&#x627;&#x62A;</label>
                                    <div class="form-line">
                                        Bottle
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="LegalStatusName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x635;&#x631;&#x641;</label>
                                    <div class="form-line">
                                        Prescription
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="ProductControlName">&#x62D;&#x627;&#x644;&#x629; &#x627;&#x644;&#x645;&#x631;&#x627;&#x642;&#x628;&#x629;</label>
                                    <div class="form-line">
                                        Uncontrolled
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="DrugTypeName">&#x646;&#x648;&#x639; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</label>
                                    <div class="form-line">
                                        Generic
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="ShelfLife">&#x645;&#x62F;&#x629; &#x627;&#x644;&#x635;&#x644;&#x627;&#x62D;&#x64A;&#x629; &#x628;&#x627;&#x644;&#x623;&#x634;&#x647;&#x631;</label>
                                    <div class="form-line">
                                        36
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="StorageConditionsName">&#x634;&#x631;&#x648;&#x637; &#x627;&#x644;&#x62A;&#x62E;&#x632;&#x64A;&#x646;</label>
                                    <div class="form-line">
                                        store below 30°c
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Price">&#x633;&#x639;&#x631; &#x627;&#x644;&#x62C;&#x645;&#x647;&#x648;&#x631; &#x628;&#x627;&#x644;&#x631;&#x64A;&#x627;&#x644;  ( &#x627;&#x644;&#x633;&#x639;&#x631; )</label>
                                    <div class="form-line">
                                        46.05
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Manufacture_NameEn" name="Manufacture.NameEn" value="DAR ALDAWA" />
                                        <label class="form-label" for="Manufacture_NameEn">&#x627;&#x644;&#x645;&#x635;&#x646;&#x639;</label>
                                        <div class="form-line">
                                            DAR ALDAWA
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Agent" name="Agent" value="[Agent 530]" />
                                        <label class="form-label">&#x627;&#x644;&#x648;&#x643;&#x64A;&#x644;</label>
                                        <div class="form-line">
                                            Salehiya Trading Co.
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <label class="form-label" for="Company_NameEn">&#x627;&#x644;&#x634;&#x631;&#x643;&#x629; &#x627;&#x644;&#x645;&#x633;&#x648;&#x642;&#x629;</label>
                                        <div class="form-line">
                                            DAR Al DAWA
                                        </div>
                                    </div>
                                </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode1">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 1</label>
                                    <div class="form-line">
                                        J01DC02
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode2">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 2</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                    </div>
                </div>
        </div>
    </div>
</div>

        </div>
    </div>
    <div id="E-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> SFDA PIL</span>
                <span style="font-size:small;">  (Patient Information Leaflet (PIL) are under review by Saudi Food and Drug Authority)</span>

            </div>
</div>


<div class="clearfix ltr">
    <div class="col-lg-12 col-md-12 col-sm-12 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="InventedNameEn">1. What this product is and what it is used for</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>Daroxime&reg;</strong> is an antibiotic used in adults and children. It works by killing bacteria that cause infections. It belongs to a group of medicines called cephalosporins.<br /><strong>Daroxime&reg;</strong> is used to treat infections of:<br />&bull; the throat<br />&bull; sinus<br />&bull; middle ear<br />&bull; the lungs or chest<br />&bull; the urinary tract<br />&bull; the skin and soft tissues.<br />Daroxime&reg; can also be used:<br />&bull; to treat Lyme disease (an infection spread by parasites called ticks).<br />Your doctor may test the type of bacteria causing your infection and monitor whether the bacteria are sensitive to <strong>Daroxime&reg;</strong> during your treatment.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="form-group clearfix">
            <label style="float: left" class="h2" for="PrecautionsEn">2. What you need to know before you use this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>Do not take Daroxime&reg;</strong><br />&bull; if you are allergic to cefuroxime axetil or any cephalosporin antibiotics or any of the other ingredients of <strong>Daroxime&reg;</strong> (listed in section 6).<br />&bull; if you have ever had a severe allergic (hypersensitive) reaction to any other type of beta lactam antibiotic (penicillins, monobactams and carbapenems).<br />If you think this applies to you, don&rsquo;t take Daroxime&reg; until you have checked with your doctor.</p><p><strong>Take special care with Daroxime&reg;</strong><br />Talk to your doctor or pharmacist before taking Daroxime&reg;.<br />Children<br /><strong>Daroxime&reg;</strong> is not recommended for children aged under 3 months, as the safety and effectiveness are not known in this age group.<br />You must look out for certain symptoms, such as allergic reactions, fungal infections (such as candida) and severe diarrhoea (pseudomembranous colitis) while you are taking Daroxime&reg;. This will reduce the risk of any problems. See &ldquo;<strong>Conditions you need to look out for</strong>&rdquo; in section.<br />If you need a blood test<br /><strong>Daroxime&reg;</strong> can affect the results of a test for blood sugar levels, or a blood screen called the Coomb&rsquo;s test. If you need a blood test: Tell the person taking the sample that you are taking <strong>Daroxime&reg;.</strong><br />Taking other medicines, herbal or dietary supplements<br />Tell your doctor or pharmacist if you are taking, have recently taken or might take any other medicines. Medicines used to reduce the amount of acid in your stomach (e.g. antacids used to treat heartburn) can affect how <strong>Daroxime&reg;</strong> works.<br />&minus; Probenecid<br />&minus; Oral anticoagulants<br />Tell your doctor or pharmacist if you are taking any medicine like this.<br />&minus; Contraceptive pills<br /><strong>Daroxime&reg;</strong> may reduce the effectiveness of the contraceptive pill. If you are taking the contraceptive pill while you are being treated with <strong>Daroxime&reg;</strong> you also need to use a barrier method of contraception (such as condoms). Ask your doctor for advice.<br /><strong>Pregnancy and breast-feeding</strong><br />If you are pregnant or breast-feeding, think you may be pregnant or are planning to have a baby, ask your doctor or pharmacist for advice before taking this medicine.<br /><strong>Driving and using machines</strong><br /><strong>Daroxime&reg;</strong> can make you dizzy and have other side effects that make you less alert.<br />Don&rsquo;t drive or use machines if you do not feel well.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="AdministrationRoutesEn">3. How to use this product.</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Always take this medicine exactly as your doctor or pharmacist has told you to. Check with your doctor or pharmacist if you are not sure.<br />Take <strong>Daroxime&reg;</strong> after food. This will help to make the treatment more effective.<br />Swallow<strong> Daroxime&reg;</strong> tablets whole with some water.<br />Don&#39;t chew, crush or split the tablets &mdash; this may make the treatment less effective.<br />The recommended dose<br /><strong>Adults</strong></p><p>The recommended dose of <strong>Daroxime&reg;</strong> is 250 mg to 500 mg twice daily depending on the severity and type of infection.</p><p><strong>Children</strong><br />The recommended dose of <strong>Daroxime&reg; </strong>is 10 mg/kg (to a maximum of 125 mg) to 15 mg/kg (to a maximum of 250 mg) twice daily depending on:<br />&bull; the severity and type of infection<br /><strong>Daroxime&reg;</strong> is not recommended for children aged under 3 months, as the safety and effectiveness are not known in this age group. Depending on the illness or how you or your child responds to treatment, the initial dose may be changed or more than one course of treatment may be needed.</p><p><br /><u>Patients with kidney problems</u><br />If you have a kidney problem, your doctor may change your dose.<br />Talk to your doctor if this applies to you.</p><p><br /><strong>If you take more Daroxime&reg; than you should</strong><br />If you take too much <strong>Daroxime&reg;</strong> you may have neurological disorders, in particular you may be more likely to have fits (seizures).<br />Don&#39;t delay. Contact your doctor or your nearest hospital emergency department immediately. If possible, show them the <strong>Daroxime&reg;</strong> pack.</p><p><br /><strong>If you forget to take Daroxime&reg;</strong><br />Do not take a double dose to make up for a forgotten dose. Just take your next dose at the usual time.</p><p><br /><strong>If you stop taking Daroxime&reg;</strong><br />Don&rsquo;t stop <strong>Daroxime&reg;</strong> without advice.<br />It is important that you take the full course of Daroxime&reg;. Don&rsquo;t stop unless your doctor advises you to &ndash; even if you are feeling better. If you don&#39;t complete the full course of treatment, the infection may come back.</p><p>If you have any further questions on the use of this medicine, ask your doctor or pharmacist.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsEn">4. Possible side effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Like all medicines, this medicine can cause side effects, although not everybody gets them.<br />Conditions you need to look out for<br />A small number of people taking cefuroxime get an allergic reaction or potentially serious skin reaction. Symptoms of these reactions include:<br />&bull; severe allergic reaction. Signs include raised and itchy rash, swelling, sometimes of the face or mouth causing difficulty in breathing.<br />&bull; skin rash, which may blister, and looks like small targets (central dark spot surrounded by a paler area, with a dark ring around the edge).</p><p>&bull; a widespread rash with blisters and peeling skin. (These may be signs of Stevens-Johnson syndrome or toxic epidermal necrolysis).</p><p><u>Other conditions you need to look out for while taking cefuroxime:</u><br />&bull; fungal infections. Medicines like cefuroxime can cause an overgrowth of yeast (Candida) in the body which can lead to fungal infections (such as thrush). This side effect is more likely if you take cefuroxime for a long time.<br />&bull; severe diarrhoea (Pseudomembranous colitis). Medicines like cefuroxime can cause inflammation of the colon (large intestine), causing severe diarrhoea, usually with blood and mucus, stomach pain, fever.<br />&bull; Jarisch-Herxheimer reaction. Some patients may get a high temperature (fever), chills, headache, muscle pain and skin rash while being treated with cefuroxime for Lyme disease. This is known as the Jarisch-Herxheimer reaction. Symptoms usually last a few hours or up to one day.<br />Contact a doctor or nurse immediately if you get any of these symptoms.</p><p><strong>Common side effects</strong><br />These may affect up to 1 in 10 people:<br />&bull; fungal infections (such as Candida)<br />&bull; headache<br />&bull; dizziness<br />&bull; diarrhoea<br />&bull; feeling sick<br />&bull; stomach pain.<br />Common side effects that may show up in blood tests:<br />&bull; an increase in a type of white blood cell (eosinophilia)<br />&bull; an increase in liver enzymes.</p><p><strong>Uncommon side effects</strong><br />These may affect up to 1 in 100 people:<br />&bull; being sick<br />&bull; skin rashes.<br />Uncommon side effects that may show up in blood tests:<br />&bull; a decrease in the number of blood platelets (cells that help blood to clot)<br />&bull; a decrease in the number of white blood cells<br />&bull; positive Coomb&rsquo;s test.</p><p><br /><strong>Other side effects</strong><br />Other side effects have occurred in a very small number of people, but their exact frequency is unknown:<br />&bull; severe diarrhoea (pseudomembranous colitis)<br />&bull; allergic reactions</p><p>&bull; skin reactions (including severe)<br />&bull; high temperature (fever)<br />&bull; yellowing of the whites of the eyes or skin<br />&bull; inflammation of the liver (hepatitis).<br />Side effects that may show up in blood tests:<br />&bull; red blood cells destroyed too quickly (haemolytic anaemia).</p><p>If any of the side effects gets serious, or if you notice any side effects not listed in this leaflet, please tell your doctor or pharmacist.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsEn">5. How to store this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>&minus; Keep medicament out of reach and sight of children.<br />&minus; Store below 30&deg;C in a dry place.<br />&minus; Do not take Daroxime&reg; after the expiry date which is printed on the outside of the pack. The expiry date refers to the last day of that month.<br />&minus; Medicines should not be disposed of via wastewater or household waste. Ask your pharmacist how to dispose of medicines no longer required. These measures will help to protect the environment.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. Further information</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsEn">a. What this product contains</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>Daroxime&reg; Film Coated Tablets </strong>contain the active ingredient Cefuroxime as (Cefuroxime axetil). Each tablet contains either 250 mg or 500 mg Cefuroxime as (Cefuroxime axetil). Inactive ingredients: Croscarmellose sodium, citric acid anhydrous, sodium bicarbonate, sodium laurilsulfate, magnesium stearate, colloidal anhydrous silica, hydrogenated vegetable oil, microcrystalline cellulose, hypromellose, titanium dioxide, macrogol.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsEn">b. What this product looks like and contents of the pack</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                Daroxime® 250 mg are white round normal biconvex film coated tablets coded (DXM 250) on one side, plain on the other one.
Daroxime® 500 mg are white oval film coated tablet coded (DXM 500) on one side.
Daroxime® Film Coated Tablets are packed in amber glass bottles covered with aluminum caps. Each bottle is enclosed in a carton along with a leaflet. Daroxime® Film Coated Tablets are available in packs of 10 or 14 tablets.
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingEn">c. Marketing Authorization Holder and Manufacturer</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Dar Al Dawa Development &amp; Investment Co. Ltd.<br />Prince Hashem Bin Al-Hussein Street<br />Na&#39;ur - Amman - Jordan<br />Tel. (+962 6) 57 27 132<br />Fax. (+962 6) 57 27 776</p><p>&nbsp;</p><p><strong>To report any side effects:<br />&bull; Jordan</strong><br />&bull; Jordan Food and Drug Administration<br />&minus; Phone :+962 6 5632000<br />&minus; Website: www.jfda.jo<br />&minus; reporting link https://primaryreporting.who-umc.org/jo<br />&minus; Email: jpc@jfda.jo</p><p><br /><strong>&bull; Saudi Arabia</strong><br />⎯ The National Pharmacovigilance Centre (NPC)<br />⎯ SFDA Call Centre: 19999<br />⎯ E-mail: npc.drug@sfda.gov.sa<br />⎯ Website: www.sfda.gov.sa/npc</p><p><br /><strong>&bull; United Arab Emirates</strong><br />o Pharmacovigilance and Medical Device Section<br />o Drug Department<br />o UAE Ministry of Health &amp; Prevention<br />&minus; Hotline: 80011111<br />&minus; Email: pv@moh.gov.ae<br />&minus; P.O. Box: 1853 Dubai UAE</p><p><br /><strong>&bull; Sudan</strong><br />⎯ National Medicines and Poisons Board (NMPB)<br />&minus; Fax: + 249 183522263<br />&minus; E-mail: info@nmpb.gov.sd<br />&minus; Website : www.nmpb.gov.sd</p><p><br /><strong>&bull; Other countries</strong><br />⎯ Please contact the relevant competent authority.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteEn">d. This leaflet was last revised in {MM/YYYY}</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                12/2022
            </div>
        </div>
    </div>
</div>    </div>
    <div id="A-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> نشرة الدواء تحت مراجعة الهيئة العامة للغذاء والدواء</span>
                <span style="font-size:small;">  (اقرأ هذه النشرة بعناية قبل البدء في استخدام هذا المنتج لأنه يحتوي على معلومات مهمة لك)</span>
            </div>
    <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr">

    </div>

</div>
<div class="clearfix rtl">
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="InventedNameAr">1. ما ھو هذا المستحضر وماھي دواعي استعماله</label>
        </div>
        <div class="form-group clearfix" style="float: right">
            <br />
            <p><strong>داروكسيم </strong>هو مضاد حيوي يستخدم في البالغين والأطفال. يعمل عن طريق القضاء على البكتيريا التي تسبب العدوى. ينتمي إلى مجموعة من الأدوية تسمى السيفالوسبورين.<br />يستخدم <strong>داروكسيم </strong>لعلاج العدوى في:<br />&bull; الحلق<br />&bull; الجيوب الأنفية<br />&bull; الأذن الوسطى<br />&bull; الرئتين أو الصدر<br />&bull; المسالك البولية<br />&bull; الجلد والأنسجة الرخوة .<br />بالإضافة إلى ذلك يستخدم <strong>داروكسيمً</strong>:<br />&bull; لعلاج مرض لايم (عدوى تنتشر عن طريق طفيليات تسمى القراد).<br />قد يقوم طبيبك بالتحقق من نوع البكتيريا المسببة للعدوى ومراقبة حساسية البكتيريا تجاه <strong>داروكسيم </strong>خلال العلاج.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="PrecautionsAr">2. ما الذي يجب عليك معرفته قبل استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p><strong>يمنع تًناول دًاروكسيم</strong></p><p>&bull; اذا كان لديك فرط حساسية تجاه سيفيوروكسيم اكسيتيل او اي من المضادات الحيوية من فئة السيفالوسبورين أو أي من المكونات الأخرى في داروكسيم(مذكورة في القسم 6).<br />&bull; اذا عانيت مسبقا من فرط حساسية شديد تجاه أي من المضادات الحيوية الأخرى من فئة<br />البيتا لاكتام (البنسيلينات, المونوباكتامات والكاربابينيمات).<br />إذا كنت تعتقد أن أي مما سبق ذكره ي نطبق عليك. لا تقم بتناول الدواء حتى تتحق ق من طبيبك.</p><p><strong>الاحتياطات عند استعمال دًاروكسيمً</strong><br />تحدث الى طبيبك قبل تناول دًًاروكسيم.ً<br /><u>الاطفال</u><br />لا ينصح بتناول <strong>داروكسيم </strong>في الأطفال الذين تقل أعمارهم عن 3 أشهر، لم يتم تحديد معلومات المأمونية والفعالية في هذه المجموعة العمرية.<br />يجب أن تتنبه لحدوث أعراض جانبية معينة مثل حدوث تفاعلات حساسية، عدوى فطرية (مثل<br />داء المبيضات) وإسهال شديد (التهاب القولون الغشائي الكاذب) خلال تناول <strong>داروكسيم</strong>. يقلل<br />ذلك من خطر حدوث أي مشاكل. انظر &quot;الحالات اًلتي تًحتاج إًلى اًلتنبه&quot; فًي القسم 4 .</p><p><u>إذا كنت بحاجة فحص الدم</u><br />قد يؤثر <strong>داروكسيمً </strong>على نتائج فحوصات مستوى السكر في الدم، أو تحليل الدم الذي يسمى بفحص كومبس. إذا كنت بحاجة فحص الدم؛ أخبر الشخص الذي يقوم بأخذ العينة أنك تتناول<br /><strong>داروكسيم</strong>.<br />&nbsp;</p><p><strong>التداخلات الدوائية من أخذ هذا المستحضر مع أي أدوية أخرى أو أعشاب أو مكملات غًًذائية</strong><br />الرجاء إخبار طبيبك أو الصيدلي إذا كنت تتناول، تناولت مؤخرا او قد تتناول أي أدوية أخرى.<br />قد تؤثر الأدوية التي تقلل كمية الحمض في المعدة(مضادات الحموضة التي تستخدم لعلاج حرقة المعدة) على طريقة عمل <strong>داروكسيم</strong>.<br />- بروبينيسيد<br />- مضادات التخثر التي تؤخذ عن طريق الفم. أخبر طبيبك إذا كنت تتناول أي من الأدوية التي تم ذكرها.<br /><strong>- حبوب مًنع اًلحملً</strong><br />قد يقلل <strong>داروكسيم </strong>من فعالية حبوب منع الحمل. في حال تناول ت حبوب منع الحمل خلال فترة<br />العلاج <strong>بداروكسيم </strong>فإنه ينبغي إستخدام وسيلة منع حمل إحتياطية إضافية(مثل إستخدام الواقي<br />الذكري). إستشيري طبيبك للحصول على النصيحة.<br /><strong>الحمل والرضاعة</strong><br />أخبري طبيبك قبل تناول <strong>داروكسيم</strong>:<br />إذا كن ت حامل او مرضع او تظنين أنك حاملا أو تنوين ذلك. اطلب استشارة طبيبك او الصيدلي<br />قبل تناول هذا الدواء.<br /><strong>تأثير دًاروكسيم عًلى اًلقيادة وًإستخدام اًلآلات</strong><br />قد يسبب <strong>داروكسيم </strong>دوار بالإضافة إلى أعراض جان بية أخرى تجعلك أقل تيقظا.<br />لا تقم بالقيادة او إستخدام الآلات إذا شعرت أنك لست على ما يرام.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            https://localhost:44358/Dashboard
            <label class="h2" for="AdministrationRoutesAr">3. ماھي طريقة استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p>تناول <strong>داروكسيم </strong>بحسب تعليما ت طبيبك أو الصيدلي. إستشر طبيبك أو الصيدلي إذا لم تكن متأكدا.<br />تناول أقراص <strong>داروكسيم </strong>بعد الطعام. يساعد ذلك على زيادة فعالية العلاج.<br />إبلع الأقراص كاملة مع الماء.<br />لا تقم بمضغ، سحق أو تقسيم الأقراص &ndash; قد يقلل ذلك من فعالية العلاج.<br /><strong>الجرعة اًلموصى بًها:</strong></p><p>الجرعة المعتادة من <strong>داروكسيم </strong>هي 250 ملغم إلى 500 ملغم مرتين يوميا بالإعتماد على شدة ونوع العدوى.<br /><strong>الأطفال</strong></p><p>الجرعة المعتادة من <strong>داروكسيم </strong>هي 10 ملغم/كغم )وصولا إلى الجرعة القصوى 125 ملغم(إلى 15 ملغم/كغم )وصولا إلى الجرعة القصوى 250 ملغم( مرتين يوميا بالإعتماد على شدة ونوع العدوى.<br />لا يوصى بإستخدام <strong>داروكسيم </strong>في الأطفال الذين تقل أعمارهم عن 3 أشهر حيث أن مأمونية وفعالية سيفيوروكسيم غير معروفة في هذه الفئة العمرية. بالإعتماد على المرض وكيفية إستجابة طفلك للعلاج، قد تتغير الجرعة الإبتدائية أو قد تحتاج إلى تكرار العلاج.<br />&nbsp;</p><p><u>المرضى الذين يعانون من مشاكل في الكلية</u><br />إذا كنت تعاني من مشاكل في الكلية، قد يقوم طبيبك بتعديل الجرعة. تحدث مع طبيبك إذا إنطبق عليك ذلك.</p><p><strong>الجرعة الزائدة من داروكسيم</strong><br />إذا تناولت جرعة زائدة من <strong>داروكسيم </strong>من الممكن أن تحدث إختلالات عصبية، وخاصة قد تزداد إحتمالية حدوث نوبات.<br />لا تؤجل الامر، تحدث مع طبيبك أو مع قسم الطوارئ في أقرب مستشفى على الفور. أحضر علبة الدواء وأظهرها للطبيب اذا امكنك ذلك<br />&nbsp;</p><p><strong>نسيان تناول جرعة داروكسيم</strong><br />لا تتناول جرعة زائدة للتعويض عن الجرعة الفائتة. تناول الجرعة التي تليها في وقتها المحدد.</p><p><strong>التوقف عًن تًناول دًاروكسيم</strong></p><p>يجب ان لا تتوقف عن تناول الدواء إلا إذا نصحك طبيبك بذلك.<br />من المهم أن تستمر بتناول داروكسيم حتى تنتهي مدة العلاج. يجب ان لا تتوقف عن تناول الدواء إلا إذا نصحك طبيبك بذلك - حتى إن شعرت بتحسن. إذا لم تقم بإنهاء فترة العلاج كاملة، قد تعود العدوى مرة أخرى.<br />اذا كان لديك اي اسئلة اضافية حول استخدام هذا الدواء، اسأل الطبيب او الصيدلي.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsAr">4. الأعراض الجانبية المحتملة</label>
        </div>
        <div class="m-r-60">
            <p>شأنه شأن الأدوية الأخرى من الممكن أن يسبب هذا الدواء أعراضا جانبية على الرغم من أنها لا تحدث مع جميع المرضى.<br /><u>الحالات التي تحتاج إلى التنبه</u><br />تحدث تفاعلات حساسية في عدد قليل من المرضى الذين يتناولون سي فيوروكسيم أو قد تحدث تفاعلات جلدية خطيرة. تتضمن ردود الافعال حدوث:<br />&bull; فرط شديد في الحساسية. تتضمن العلامات حدوث: طفح ظاهر مع حكة، تورم، يحدث أحيانا في الوجه أو الفم مما يسبب حدوث صعوبة في التنفس.<br />&bull; طفح جلدي والذي قد يكون على شكل تقرحات ويظهر كأهداف صغيرة(نقطة غامقة اللون وسطية محاطة بمساحة لونها فاتح مع حلقات غامقة اللون تحيط بالحافة).<br />&bull; إنتشار طفح جلدي وتقرحات وتقشر الجلد (قد تكون هذه علامات حدوث متلازمة ستيفنز جونسون أو انحلال البشرة السمي).<br /><u>حالات أخرى قد تحتاج إلى التنبه لها خلال تناول سيف يوروكسيم:</u><br />&bull; عدوى فطرية. الأدوية التي تشبه سيفيوروكسيم قًًد تسبب فرط في نمو الفطريات(مثل داء المبيضات) في الجسم مما قد يسبب حدوث عدوى فطرية (مثل القلاع). قد يحدث ذلك إذا تناولت سيفيوروكسيم لفترة زمنية طويلة الأمد.<br />&bull; إسهال شديد(إلتهاب القولون الغشائي الكاذب). قد تسبب الأدوية مثل سيفيوروكسيمً حدوث إلتهاب في القولون(الأمعاء الغليظة)، مما يسبب حدوث إسهال، يصاحبه عادة دم ومخاط، ألم في المعدة، حمى.<br />&bull; رد فعل ياريش هيكسهايمر. قد يحدث إرتفاع في درجة الحرارة(حمى) عند بعض المرضى، قشعريرة، صداع، ألم عضلي وطفح جلدي خلال إستخدام سيفيوروكسيم لعلاج مرض لايم. يعرف ذلك بإسم رد فعل ياريش هيكسهايمر. قد تستمر هذه الأعراض من بضع ساعات إلى يوم.</p><p>تحدث مع طبيبك أو الممرض على الفور في حال حدوث أي من هذه الاعراض.</p><p><br /><strong>أعراض جًانبية شًائعة</strong></p><p>قد يؤثر على شخ ص من ك ل 10 أشخاص:<br />&bull; عدوى فطرية (مثل داء المبيضات)<br />&bull; صداع<br />&bull; دوار<br />&bull; إسهال</p><p>&bull; غثيان<br />&bull; ألم في المعدة .<br />أعراض جانبية شائعة قد تظهر في فحوصات الدم:<br />&bull; ارتفاع في نوع من خلايا الدم البيضاء (كثرة الحمضات)<br />&bull; ارتفاع إنزيمات الكبد .<br />&nbsp;</p><p><strong>أعراض جًانبية غًير شًائعة</strong></p><p>قد يؤثر على شخص من كل 100 شخ ص:<br />&bull; غثيان<br />&bull; طفح جلدي<br />أعراض جانبية غير شائعة قد تظهر في فحوصات الدم:<br />&bull; إنخفاض عدد الصفائح الدموية (الخلايا التي تساعد الدم على التخثر)<br />&bull; إنخفاض عدد خلايا الدم البيضاء<br />&bull; فحص كومبس إيجابي.</p><p><strong>أعراض جًانبية أًخرى</strong></p><p>أعراض جانبية أخرى حدثت في عدد قليل من المرضى، لكن معدل التكرار غير معروف:<br />&bull; إسهال شديد (إلتهاب الغشاء القولوني الكاذب)<br />&bull; تفاعلات حساسية<br />&bull; تفاعلات جلدية (قد تكون شديدة)<br />&bull; إرتفاع درجة الحرارة (حمى)<br />&bull; إصفرار بياض العين أو الجلد<br />&bull; إلتهاب الكبد<br />أعراض جانبية قد تظهر في فحوصات الدم:<br />&bull; انحلال خلايا الدم الحمراء بسرعة عالية (فقر الدم الإنحلالي).</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsAr">5. طريقة تخزين المستحضر</label>
        </div>
        <div class="m-r-60">
            <p>&bull; يحفظ بعيدا عن متناول ايدي الاطفال ونظرهم .<br />&bull; يحفظ دون 30 درجة مئوية في مكان جاف.<br />&bull; لا تستخدم <strong>داروكسيم </strong>بعد تاريخ الانتهاء المذكور على العبوة الخارجية. يدل تاريخ الانتهاء على اخر يوم في الشهر المذكور.<br />&bull; يجب عدم التخلص من الأدوية في المياه العادمة أو النفايات المنزلية. إسأل الصيدلي حول الطريقة السليمة للتخلص من الأدوية التي لم تعد بحاجة إليها. سيساعد هذا في حماية البيئة.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: right">6. معلومات أخرى</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsAr">أ‌. على ماذا يحتوي هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p>المادة الفعالة في أقراص داروكسيم هي سيفيوروكسيم(على هيئة سيفيوروكسيم أكسيتيل).<br />تتوفر أقراص داروكسيم بتراكيز 250 و 500 ملغم.<br />المواد غًير اًلفعالة اًلأخرى هًي:ً كروس كارميلوس صوديوم، حمض السيتريك اللامائي،<br />بيكربونات الصوديوم، ملح الصوديوم للوريل السلفات، ستيارات الماغنيسيوم، سيليكا غروية<br />لامائية، زيت نباتي مهدرج، سيليلوز دقيق البلورية، هيبروميلوز، ثاني أكسيد التيتانيوم،<br />ماكروغول.</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsAr">ب‌. كيف يبدو شكل هذا المستحضر وماهي محتويات العلبة</label>
        </div>
        <div class="m-r-60">
            <p><strong>داروكسيم 250 مًًلغم</strong> أقراص مغلفة مستديرة بيضاء اللون محدبة الوجهي ن مرمزة بالرمز<br />(DXM 250) على جهة واحدة، فارغة على الجهة الاخرى.<br /><strong>داروكسيم 500 مًلغم</strong> أًقراص مغلفة بيضاوية الشكل بيضاء اللون مرمزة بالرمز<br />( DXM 500) على جهة واحدة.<br />اقراص داروكسيم معبأة داخل قارورة زجاجية عنبرية مغلقة بواسطة غطاء من الالمنيوم. هذه القارورة تغلف داخل علبة كرتونية الى جانب نشرة.</p><p>تتوفر أقراص داروكسيم المغلفة في عبوات تحتوي على 10 أقرا ص أو 14 قرص .</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingAr">ت‌. الشركة المصنعة ومالك حق التسويق</label>
        </div>
        <div class="m-r-60">
            <p>شركة دار الدواء للتنمية والاستثمار المساهمة المحدودة<br />شارع الأمير هاشم بن الحسين<br />ناعور - عمان - الاردن<br />هاتف. 132 27 57 ( 6 962 ) +<br />فاكس. 776 27 57 ( 6 962 ) +</p><p><strong>للإبلاغ&nbsp;عًن اًلأعراضاًلجانبية :ًً</strong></p><ul><li><strong>الأردنً</strong></li></ul><p>&nbsp;المؤسسة العامة للغذاء والدواء<br />&minus; الرقم: 0096265632000<br />&minus; الموقع الالكتروني: www.jfda.jo<br />رابط التبليغ: https://primaryreporting.who-umc.org/jo<br />- البريد الالكتروني: jpc@jfda.jo</p><ul><li><strong>&nbsp;المملكة العربية السعودية</strong></li></ul><p>&minus; المركز الوطني للتيقظ والسلامة الدوائية<br />&minus; الرقم الموحد 19999<br />&minus; البريد الالكتروني: npc.drug@sfda.gov.sa<br />&minus; الموقع الالكتروني www.sfda.gov.sa/npc</p><ul><li><strong>الإمارات العربية المتحدة</strong></li></ul><p>&nbsp;قسم اليقظة الدوائية والوسائل الطبية<br />o إدارة الدواء<br />o وزارة الصحة ووقاية المجتمع<br />&minus; الخط الساخ ن ٨٠٠١١١١١&nbsp;<br />&minus; ايميل : pv@moh.gov.ae<br />&minus; صندوق بريد ١٨٥٣ دبي الامارات العربية المتحدة</p><ul><li><strong>&nbsp;السودان</strong></li></ul><p>&minus; المجلس القومي للأدوية والسموم<br />o فاكس: 522263 183 ( 249 )+<br />o البريد الإلكتروني: info@nmpb.gov.sd<br />o الموقع الإلكتروني: www.nmpb.gov.sd</p><ul><li><strong>&nbsp;الدول الأخرى</strong></li></ul><p>- الرجاء الاتصال بالمؤسسات والهيئات الوطنية في كل دولة</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteAr">ث‌. تمت مراجعة هذه النشرة في التاريخ الذي تمت فيه مراجعة النشرة بالشهر والسنة</label>
        </div>
        <div class="m-r-60">
            12/2022
        </div>
    </div>
</div>
    </div>
    <div id="M-div" class="box-data">


    <div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr"><i class="fa fa-info-circle"></i>&nbsp;Read this leaflet carefully before you start using this product as it contains important information for you</div>
    </div>
<div class="row clearfix ltr">

    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="MedicinalName">1. NAME OF THE MEDICINAL PRODUCT </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Daroxime 500 mg Film Coated Tablets
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="QualitativeQuantitativeComposition">2. QUALITATIVE AND QUANTITATIVE COMPOSITION </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Each Film Coated Tablet contains 500 mg Cefuroxime (as cefuroxime axetil).
For a full list of excipients, see section 6.1
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="DosageForm">3. PHARMACEUTICAL FORM </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Film coated tablets
Daroxime 500 mg tablets are white oval film coated tablets coded (DXM 500) on one side.
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">4. CLINICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="TherapeuticIndications">4.1 Therapeutic Indications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Daroxime is indicated for the treatment of the infections listed below in adults and children from the age of 3 months (see sections 4.4 and 5.1).<br />&bull; Acute streptococcal tonsillitis and pharyngitis.<br />&bull; Acute bacterial sinusitis.<br />&bull; Acute otitis media.<br />&bull; Acute exacerbations of chronic bronchitis.<br />&bull; Cystitis.<br />&bull; Pyelonephritis.<br />&bull; Uncomplicated skin and soft tissue infections.<br />&bull; Treatment of early Lyme disease.</p><p>Consideration should be given to official guidance on the appropriate use of antibacterial agents.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PosologyAndMethodAdministration">4.2 Posology And Method Administration</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Posology</u></p><p>The usual course of therapy is seven days (may range from five to ten days).</p><p>Table 1. Adults and children (&ge;40 kg)</p><table border="1" cellspacing="1" cellpadding="1" style="width:500px"><tbody><tr><td style="text-align:center; width:249px"><strong>Indication</strong></td><td style="text-align:center; width:249px"><strong>Dosage</strong></td></tr><tr><td style="width:249px">&nbsp;Acute tonsillitis and pharyngitis, acute bacterial sinusitis</td><td style="width:249px">250 mg twice daily</td></tr><tr><td style="width:249px">Acute otitis media</td><td style="width:249px">500 mg twice daily</td></tr><tr><td style="width:249px">Acute exacerbations of chronic bronchitis</td><td style="width:249px">500 mg twice daily</td></tr><tr><td style="width:249px">Cystitis</td><td style="width:249px">250 mg twice daily</td></tr><tr><td style="width:249px">Pyelonephritis</td><td style="width:249px">250 mg twice daily</td></tr><tr><td style="width:249px">Uncomplicated skin and soft tissue infections</td><td style="width:249px">250 mg twice daily</td></tr><tr><td style="width:249px">Lyme disease</td><td style="width:249px">500 mg twice daily for 14 days (range of 10 to 21 days)</td></tr></tbody></table><p>&nbsp;</p><p>Table 2. Children (&lt;40 kg).</p><table border="1" cellspacing="1" cellpadding="1" style="width:500px"><tbody><tr><td style="text-align:center; width:249px"><strong>Indication</strong></td><td style="text-align:center; width:249px"><strong>Dosage</strong></td></tr><tr><td style="width:249px">Acute tonsillitis and pharyngitis, acute bacterial sinusitis</td><td style="width:249px">10 mg/kg twice daily to a maximum of 125 mg twice daily</td></tr><tr><td style="width:249px">Children aged two years or older with otitis media or, where appropriate, with more severe infections</td><td style="width:249px">15 mg/kg twice daily to a maximum of 250 mg twice daily</td></tr><tr><td style="width:249px">Cystitis</td><td style="width:249px">15 mg/kg twice daily to a maximum of 250 mg twice daily</td></tr><tr><td style="width:249px">Pyelonephritis</td><td style="width:249px">15 mg/kg twice daily to a maximum of 250 mg twice daily for 10 to 14 days</td></tr><tr><td style="width:249px">Uncomplicated skin and soft tissue infections</td><td style="width:249px">15 mg/kg twice daily to a maximum of 250 mg twice daily</td></tr><tr><td style="width:249px">Lyme disease</td><td style="width:249px">15 mg/kg twice daily to a maximum of 250 mg twice daily for 14 days (10 to 21 days)</td></tr></tbody></table><p>&nbsp;</p><p>There is no experience of using cefuroxime in children under the age of 3 months.</p><p>Cefuroxime axetil tablets and cefuroxime axetil suspension are not bioequivalent and are not substitutable on a milligram-per-milligram basis (see section 5.2).</p><p>Renal impairment</p><p>The safety and efficacy of cefuroxime axetil in patients with renal failure have not been established.</p><p>Cefuroxime is primarily excreted by the kidneys. In patients with markedly impaired renal function it is recommended that the dosage of cefuroxime should be reduced to compensate for its slower excretion. Cefuroxime is effectively removed by dialysis.</p><p>&nbsp;</p><p>Table 3. Recommended doses for Daroxime in renal impairment</p><table border="1" cellspacing="1" cellpadding="1" style="width:500px"><tbody><tr><td style="width:202px">Creatinine clearance</td><td style="width:138px">T1/2 (hrs)</td><td style="width:158px">Recommended dosage</td></tr><tr><td style="width:202px">&ge;30 ml/min/1.73 m2</td><td style="width:138px">&nbsp;1.4-2.4</td><td style="width:158px">no dose adjustment necessary (standard dose of 125 mg to 500 mg given twice daily)</td></tr><tr><td style="width:202px">10-29 ml/min/1.73 m2</td><td style="width:138px">4.6</td><td style="width:158px">standard individual dose given every 24 hours</td></tr><tr><td style="width:202px">&lt;10 ml/min/1.73 m2</td><td style="width:138px">&nbsp;16.8</td><td style="width:158px">standard individual dose given every 48 hours</td></tr><tr><td style="width:202px">During haemodialysis</td><td style="width:138px">&nbsp;2-4</td><td style="width:158px">a single additional standard individual dose should be given at the end of each dialysis</td></tr></tbody></table><p>Hepatic impairment</p><p>There are no data available for patients with hepatic impairment. Since cefuroxime is primarily eliminated by the kidney, the presence of hepatic dysfunction is expected to have no effect on the pharmacokinetics of cefuroxime.</p><p>Method of administration</p><p>Oral use</p><p>Daroxime tablets should be taken after food for optimum absorption.</p><p>Daroxime tablets should not be crushed and are therefore unsuitable for treatment of patients who cannot swallow tablets.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Contraindications">4.3 Contraindications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Hypersensitivity to cefuroxime or to any of the excipients listed in section 6.1. Patients with known hypersensitivity to cephalosporin antibiotics. History of severe hypersensitivity (e.g. anaphylactic reaction) to any other type of betalactam antibacterial agent (penicillins, monobactams and carbapenems).
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialWarnings">4.4. Special warnings and precautions for use</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Hypersensitivity reactions</u></p><p>Special care is indicated in patients who have experienced an allergic reaction to penicillins or other beta-lactam antibiotics because there is a risk of cross-sensitivity. As with all beta-lactam antibacterial agents, serious and occasionally fatal hypersensitivity reactions have been reported. In case of severe hypersensitivity reactions, treatment with cefuroxime must be discontinued immediately and adequate emergency measures must be initiated.</p><p>Before beginning treatment, it should be established whether the patient has a history of severe hypersensitivity reactions to cefuroxime, to other cephalosporins or to any other type of beta-lactam agent. Caution should be used if cefuroxime is given to patients with a history of non-severe hypersensitivity to other beta-lactam agents.</p><p><u>Jarisch-Herxheimer reaction </u></p><p>The Jarisch-Herxheimer reaction has been seen following cefuroxime axetil treatment of Lyme disease. It results directly from the bactericidal activity of cefuroxime axetil on the causative bacteria of Lyme disease, the spirochaete Borrelia burgdorferi. Patients should be reassured that this is a common and usually self-limiting consequence of antibiotic treatment of Lyme disease (see section 4.8).</p><p><u>Overgrowth of non-susceptible microorganisms</u></p><p>As with other antibiotics, use of cefuroxime axetil may result in the overgrowth of Candida. Prolonged use may also result in the overgrowth of other non-susceptible microorganisms (e.g. enterococci and Clostridium difficile), which may require interruption of treatment (see section 4.8).</p><p>Antibacterial agent&ndash;associated pseudomembranous colitis have been reported with nearly all antibacterial agents, including cefuroxime and may range in severity from mild to life threatening. This diagnosis should be considered in patients with diarrhoea during or subsequent to the administration of cefuroxime (see section 4.8). Discontinuation of therapy with cefuroxime and the administration of specific treatment for Clostridium difficile should be considered. Medicinal products that inhibit peristalsis should not be given (see section 4.8).</p><p><u>Interference with diagnostic tests</u></p><p>The development of a positive Coombs Test associated with the use of cefuroxime may interfere with cross matching of blood (see section 4.8).</p><p>As a false negative result may occur in the ferricyanide test, it is recommended that either the glucose oxidase or hexokinase methods are used to determine blood/plasma glucose levels in patients receiving cefuroxime axetil.</p><p><u>Important information about excipients</u></p><p>Daroxime tablets contain less than 1 mmol (23 mg) of sodium, that is to say essentially &#39;sodium free&#39;.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="InteractionsOtherMedicines">4.5. Interactions with other medicinal products</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Drugs which reduce gastric acidity may result in a lower bioavailability of cefuroxime axetil compared with that of the fasting state and tend to cancel the effect of enhanced absorption after food.</p><p>Cefuroxime axetil may affect the gut flora, leading to lower oestrogen reabsorption and reduced efficacy of combined oral contraceptives.</p><p>Cefuroxime is excreted by glomerular filtration and tubular secretion. Concomitant use of probenicid is not recommended. Concurrent administration of probenecid significantly increases the peak concentration, area under the serum concentration time curve and elimination half-life of cefuroxime.</p><p>Concomitant use with oral anticoagulants may give rise to increased INR.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="FertilityAndPregnantWarnings">4.6. Fertility, pregnancy and lactation</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Pregnancy </u></p><p>There are limited data from the use of cefuroxime in pregnant women. Studies in animals have shown no harmful effects on pregnancy, embryonal or foetal development, parturition or postnatal development. Daroxime should be prescribed to pregnant women only if the benefit outweighs the risk.</p><p><u>Breastfeeding</u></p><p>Cefuroxime is excreted in human milk in small quantities. Adverse effects at therapeutic doses are not expected, although a risk of diarrhoea and fungus infection of the mucous membranes cannot be excluded. Breastfeeding might have to be discontinued due to these effects. The possibility of sensitisation should be taken into account. Cefuroxime should only be used during breastfeeding after benefit/risk assessment by the physician in charge.</p><p><u>Fertility </u></p><p>There are no data on the effects of cefuroxime axetil on fertility in humans. Reproductive studies in animals have shown no effects on fertility.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="EffectsAbilityDriveMachines">4.7. Effects on ability to drive and use machines</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>No studies on the effects on the ability to drive and use machines have been performed. However, as this medicine may cause dizziness, patients should be warned to be cautious when driving or operating machinery.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="UndesirableEffects">4.8. Undesirable effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><strong>4.8.1 Adverse reactions:</strong><br />The most common adverse reactions are Candida overgrowth, eosinophilia, headache, dizziness, gastrointestinal disturbances and transient rise in liver enzymes.</p><p><strong>4.8.2 Clinical Studies</strong></p><p>Experience The frequency categories assigned to the adverse reactions below are estimates, as for most reactions suitable data (for example from placebo-controlled studies) for calculating incidence were not available. In addition the incidence of adverse reactions associated with cefuroxime axetil may vary according to the indication.</p><p>Data from large clinical studies were used to determine the frequency of very common to rare undesirable effects. The frequencies assigned to all other undesirable effects (i.e. those occurring at &lt;1/10,000) were mainly determined using post-marketing data and refer to a reporting rate rather than true frequency. Placebo-controlled trial data were not available.</p><p>Where incidences have been calculated from clinical trial data. Within each frequency grouping, undesirable effects are presented in order of decreasing seriousness.</p><p>Treatment related adverse reactions, all grades, are listed below by MedDRA body system organ class, frequency and grade of severity. The following convention has been utilised for the classification of frequency: very common &ge; 1/10; common &ge; 1/100 to &lt; 1/10, uncommon &ge; 1/1,000 to &lt; 1/100; rare &ge; 1/10,000 to &lt; 1/1,000; very rare &lt; 1/10,000 and not known (cannot be estimated from the available data).</p><table border="1" cellspacing="1" cellpadding="1" style="width:500px"><tbody><tr><td style="text-align:center; width:159px"><strong>System organ class</strong></td><td style="text-align:center; width:159px"><strong>Common</strong></td><td style="text-align:center; width:98px"><strong>Uncommon</strong></td><td style="text-align:center; width:83px"><strong>Not known</strong></td></tr><tr><td style="width:159px">Infections and infestations</td><td style="width:159px">Candida overgrowth</td><td style="width:98px">&nbsp;</td><td style="width:83px">Clostridium difficile overgrowth</td></tr><tr><td style="width:159px">Blood and lymphatic system disorders</td><td style="width:159px">eosinophilia</td><td style="width:98px">positive Coomb&#39;s test, thrombocytopenia, leukopenia (sometimes profound)</td><td style="width:83px">haemolytic anaemia</td></tr><tr><td style="width:159px">Immune system disorders</td><td style="width:159px">&nbsp;</td><td style="width:98px">&nbsp;</td><td style="width:83px">drug fever, serum sickness, anaphylaxis, Jarisch-Herxheimer reaction</td></tr><tr><td style="width:159px">Nervous system disorders</td><td style="width:159px">headache, dizziness</td><td style="width:98px">&nbsp;</td><td style="width:83px">&nbsp;</td></tr><tr><td style="width:159px">Gastrointestinal disorders</td><td style="width:159px">diarrhoea, nausea, abdominal pain</td><td style="width:98px">vomiting</td><td style="width:83px">pseudomembranous colitis (see section 4.4)</td></tr><tr><td style="width:159px">Hepatobiliary disorders</td><td style="width:159px">transient increases of hepatic enzyme levels</td><td style="width:98px">&nbsp;</td><td style="width:83px">jaundice (predominantly cholestatic), hepatitis</td></tr><tr><td style="width:159px">Skin and subcutaneous tissue disorders</td><td style="width:159px">&nbsp;</td><td style="width:98px">skin rashes</td><td style="width:83px">urticaria, pruritus, erythema multiforme, Stevens-Johnson syndrome, toxic epidermal necrolysis (exanthematic necrolysis) (see Immune system disorders), angioneurotic oedema</td></tr><tr></tr></tbody></table><p>Description of selected adverse reactions<br />Cephalosporins as a class tend to be absorbed onto the surface of red cells membranes and react with antibodies directed against the drug to produce a positive Coombs test (which can interfere with cross-matching of blood) and very rarely haemolytic anaemia.<br />Transient rises in serum liver enzymes have been observed which are usually reversible.</p><p><strong>Paediatric population</strong></p><p>The safety profile for cefuroxime axetil in children is consistent with the profile in adults.</p><p><strong>To report any side effect(s):<br />Saudi Arabia:</strong><br />&bull; The National Pharmacovigilance Centre (NPC):<br />- SFDA Call Center: 19999<br />- E-mail: npc.drug@sfda.gov.sa<br />- Website: https://ade.sfda.gov.sa/</p><p><strong>Other GCC States:</strong><br />- Please contact the relevant competent authority.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Overdoes">4.9. Overdoes</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Overdose can lead to neurological sequelae including encephalopathy, convulsions and coma. Symptoms of overdose can occur if the dose is not reduced appropriately in patients with renal impairment (see sections 4.2 and 4.4).</p><p>Serum levels of cefuroxime can be reduced by haemodialysis and peritoneal dialysis.</p>
            </div>
        </div>
    </div>

    <div class="col-xs-12">
        <label style="float: left">5. PHARMACOLOGICAL PROPERTIES</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PharmacodynamicProperties">5.1. Pharmacodynamic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Pharmacotherapeutic group: antibacterials for systemic use, second-generation cephalosporins, ATC code: J01DC02</p><p>Mechanism of action</p><p>Cefuroxime axetil undergoes hydrolysis by esterase enzymes to the active antibiotic, cefuroxime.</p><p>Cefuroxime inhibits bacterial cell wall synthesis following attachment to penicillin binding proteins (PBPs). This results in the interruption of cell wall (peptidoglycan) biosynthesis, which leads to bacterial cell lysis and death.</p><p>Mechanism of resistance</p><p>Bacterial resistance to cefuroxime may be due to one or more of the following mechanisms:<br />&bull; hydrolysis by beta-lactamases; including (but not limited to) by extended-spectrum beta-lactamases (ESBLs), and AmpC enzymes that may be induced or stably derepressed in certain aerobic Gram-negative bacteria species;<br />&bull; reduced affinity of penicillin-binding proteins for cefuroxime;<br />&bull; outer membrane impermeability, which restricts access of cefuroxime to penicillin binding proteins in Gram-negative bacteria;<br />&bull; bacterial efflux pumps.</p><p>Organisms that have acquired resistance to other injectable cephalosporins are expected to be resistant to cefuroxime.</p><p>Depending on the mechanism of resistance, organisms with acquired resistance to penicillins may demonstrate reduced susceptibility or resistance to cefuroxime.</p><p><strong>Cefuroxime axetil breakpoints</strong></p><p>Minimum inhibitory concentration (MIC) breakpoints established by the European Committee on Antimicrobial Susceptibility Testing (EUCAST) are as follows:</p><table border="1" cellspacing="1" cellpadding="1" style="width:500px"><tbody><tr><td style="text-align:center; width:254px"><strong>Microorgansim&nbsp;</strong></td><td rowspan="1" colspan="2" style="text-align:center; width:121px"><strong>Breakpoints (mg/L)</strong></td></tr><tr><td style="width:254px">&nbsp;</td><td style="width:121px">S</td><td style="width:123px">R</td></tr><tr><td style="width:254px">Enterobacteriaceae 1, 2</td><td style="width:121px">&le;8</td><td style="width:123px">&gt;8</td></tr><tr><td style="width:254px">Staphylococcus spp.</td><td style="width:121px">Note3</td><td style="width:123px">Note3</td></tr><tr><td style="width:254px">Streptococcus A, B, C and G</td><td style="width:121px">Note4</td><td style="width:123px">Note4</td></tr><tr><td style="width:254px">Streptococcus pneumoniae</td><td style="width:121px">&le;0.25</td><td style="width:123px">&gt;0.5</td></tr><tr><td style="width:254px">Moraxella catarrhalis</td><td style="width:121px">&le;0.125</td><td style="width:123px">&gt;4</td></tr><tr><td style="width:254px">Haemophilus influenzae</td><td style="width:121px">&le;0.125</td><td style="width:123px">&gt;1</td></tr><tr><td style="width:254px">Non-species related breakpoints1</td><td style="width:121px">IE5</td><td style="width:123px">IE5</td></tr><tr><td colspan="3" style="width:254px"><span>&nbsp;</span>1 The cephalosporin breakpoints for Enterobacteriaceae will detect all clinically important resistance mechanisms (including ESBL and plasmid mediated AmpC). Some strains that produce beta-lactamases are susceptible or intermediate to 3rd or 4th generation cephalosporins with these breakpoints and should be reported as found, i.e. the presence or absence of an ESBL does not in itself influence the categorization of susceptibility. In many areas, ESBL detection and characterization is recommended or mandatory for infection control purposes.<br />2 Uncomplicated UTI (cystitis) only (see section 4.1).<br />3 Susceptibility of staphylococci to cephalosporins is inferred from the methicillin susceptibility except for ceftazidme and cefixime and ceftibuten, which do not have breakpoints and should not be used for staphylococcal infections.<br />4 The beta-lactam susceptability of beta-haemolytic streptococci groups A, B, C and G is inferred from the penicillin susceptibility.<br />5 insufficient evidence that the species in question is a good target for therapy with the drug. An MIC with a comment but without an accompanying S or R-categorization may be reported.</td></tr></tbody></table><p>S=susceptible, R=resistant</p><p>Microbiological susceptibility</p><p>The prevalence of acquired resistance may vary geographically and with time for selected species and local information on resistance is desirable, particularly when treating severe infections. As necessary, expert advice should be sought when the local prevalence of resistance is such that the utility of cefuroxime axetil in at least some types of infections is questionable.</p><p>Cefuroxime is usually active against the following microorganisms in vitro.</p><p><strong>Commonly susceptible species:</strong></p><p>Gram-positive aerobes:<br />Staphylococcus aureus (methicillin susceptible)*<br />Coagulase negative staphylococcus (methicillin susceptible)<br />Streptococcus pyogenes<br />Streptococcus agalactiae<br />Gram-negative aerobes:<br />Haemophilus influenzae<br />Haemophilus parainfluenzae<br />Moraxella catarrhalis<br />Spirochaetes:<br />Borrelia burgdorferi</p><p><strong>Microorganisms for which acquired resistance may be a problem</strong><br />Gram-positive aerobes:<br />Streptococcus pneumoniae<br />Gram-negative aerobes:<br />Citrobacter freundii<br />Enterobacter aerogenes<br />Enterobacter cloacae<br />Escherichia coli<br />Klebsiella pneumoniae<br />Proteus mirabilis<br />Proteus spp.(other than P. vulgaris)<br />Providencia spp.<br />Gram-positive anaerobes:<br />Peptostreptococcus spp.<br />Propionibacterium spp.<br />Gram-negative anaerobes:<br />Fusobacterium spp.<br />Bacteroides spp.<br /><strong>Inherently resistant microorganisms</strong><br />Gram-positive aerobes:<br />Enterococcus faecalis<br />Enterococcus faecium<br />Gram-negative aerobes:<br />Acinetobacter spp.<br />Campylobacter spp.<br />Morganella morganii<br />Proteus vulgaris<br />Pseudomonas aeruginosa<br />Serratia marcescens<br />Gram-negative anaerobes:<br />Bacteroides fragilis</p><p><strong>Others:</strong><br />Chlamydia spp.<br />Mycoplasma spp.<br />Legionella spp.</p><p>* All methicillin-resistant S. aureus are resistant to cefuroxime</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
                <label style="float: left" for="PharmacokineticProperties">5.2. Pharmacokinetic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><strong>Absorption</strong></p><p>After oral administration cefuroxime axetil is absorbed from the gastrointestinal tract and rapidly hydrolysed in the intestinal mucosa and blood to release cefuroxime into the circulation. Optimum absorption occurs when it is administered shortly after a meal.</p><p>Following administration of cefuroxime axetil tablets peak serum levels (2.1 mcg/ml for a 125 mg dose, 4.1 mcg/ml for a 250 mg dose, 7.0 mcg/ml for a 500 mg dose and 13.6 mcg/ml for a 1000 mg dose) occur approximately 2 to 3 hours after dosing when taken with food. The rate of absorption of cefuroxime from the suspension is reduced compared with the tablets, leading to later, lower peak serum levels and reduced systemic bioavailability (4 to 17% less). Cefuroxime axetil oral suspension was not bioequivalent to cefuroxime axetil tablets when tested in healthy adults and therefore is not substitutable on a milligram-per-milligram basis (see section 4.2).The pharmacokinetics of cefuroxime is linear over the oral dosage range of 125 to 1000 mg. No accumulation of cefuroxime occurred following repeat oral doses of 250 to 500 mg.</p><p><strong>Distribution</strong></p><p>Protein binding has been stated as 33 to 50% depending on the methodology used. Following a single dose of cefuroxime axetil 500 mg tablet to 12 healthy volunteers, the apparent volume of distribution was 50 L (CV%=28%). Concentrations of cefuroxime in excess of the minimum inhibitory levels for common pathogens can be achieved in the tonsilla, sinus tissues, bronchial mucosa, bone, pleural fluid, joint fluid, synovial fluid, interstitial fluid, bile, sputum and aqueous humor. Cefuroxime passes the blood-brain barrier when the meninges are inflamed.</p><p><strong>Biotransformation</strong></p><p>Cefuroxime is not metabolised.</p><p><strong>Elimination</strong></p><p>The serum half-life is between 1 and 1.5 hours. Cefuroxime is excreted by glomerular filtration and tubular secretion. The renal clearance is in the region of 125 to 148 ml/min/1.73 m2.</p><p><strong>Special patient populations</strong></p><p><strong>Gender</strong></p><p>No differences in the pharmacokinetics of cefuroxime were observed between males and females.</p><p><strong>Elderly</strong></p><p>No special precaution is necessary in the elderly patients with normal renal function at dosages up to the normal maximum of 1 g per day. Elderly patients are more likely to have decreased renal function; therefore, the dose should be adjusted in accordance with the renal function in the elderly (see section 4.2).</p><p><strong>Paediatrics</strong></p><p>In older infants (aged &gt;3 months) and in children, the pharmacokinetics of cefuroxime are similar to that observed in adults.</p><p>There is no clinical trial data available on the use of cefuroxime axetil in children under the age of 3 months.</p><p><strong>Renal impairment</strong></p><p>The safety and efficacy of cefuroxime axetil in patients with renal failure have not been established. Cefuroxime is primarily excreted by the kidneys. Therefore, as with all such antibiotics, in patients with markedly impaired renal function (i.e. C1cr &lt;30 ml/minute) it is recommended that the dosage of cefuroxime should be reduced to compensate for its slower excretion (see section 4.2). Cefuroxime is effectively removed by dialysis.</p><p><strong>Hepatic impairment</strong></p><p>There are no data available for patients with hepatic impairment. Since cefuroxime is primarily eliminated by the kidney, the presence of hepatic dysfunction is expected to have no effect on the pharmacokinetics of cefuroxime.</p><p><strong>Pharmacokinetic/pharmacodynamic relationship</strong></p><p>For cephalosporins, the most important pharmacokinetic-pharmacodynamic index correlating with in vivo efficacy has been shown to be the percentage of the dosing interval (%T) that the unbound concentration remains above the minimum inhibitory concentration (MIC) of cefuroxime for individual target species (i.e. %T&gt;MIC).</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PreclinicalSafetyData">5.3 Preclinical Safety Data</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Non-clinical data reveal no special hazard for humans based on studies of safety pharmacology, repeated dose toxicity, genotoxicity and toxicity to reproduction and&nbsp;development. No carcinogenicity studies have been performed; however, there is no evidence to suggest carcinogenic potential.</p><p>Gamma glutamyl transpeptidase activity in rat urine is inhibited by various cephalosporins, however the level of inhibition is less with cefuroxime. This may have significance in the interference in clinical laboratory tests in humans</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. PHARMACEUTICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ExcipientsList">6.1 Excipients List</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><strong>Core:</strong></p><ul><li>Croscarmellose sodium</li><li>Citric acid</li><li>Colloidal anhydrous silica</li><li>Sodium bicarbonate</li><li>Sodium laurilsulfate</li><li>Hydrogenated vegetable oil</li><li>Magnesium stearate</li><li>Microcrystalline cellulose</li></ul><p><strong>Film Coat:</strong></p><ul><li>Titanium dioxide,</li><li>Macrogol 400</li><li>Hypromellose.</li></ul>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Incompatibilities">6.2. Incompatibilities</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>A positive Coombs&#39; test has been reported during treatment with cephalosporins - this phenomenon can interfere with cross-matching of blood</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ShelfLife">6.3. Shelf Life</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                36 months
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PrecautionsStorageConditions">6.4. Special precautions for storage</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Store below 30&deg;C in a dry place.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ContainerContents">6.5. Nature and contents of container</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Primary packaging: amber glass Bottle with gold aluminum pilfer proof roll on cap containing 10 or 14 tablets. Secondary packaging: Carton, Label and Leaflet.</p><p>Not all pack sizes may be marketed</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialPrecautionsDisposal">6.6. Special precautions for disposal and other handling</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>No special requirements.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="AuthorizationMarketingHolder">7. MARKETING AUTHORISATION HOLDER</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Dar Al Dawa Development & Investment Co Ltd
Prince Hashem Bin Al-Hussein Street.
Na'ur – Amman – Jordan.
Tel. (+962 6) 57 27 132
Fax. (+962 6) 57 27 776
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="RevisionDateText">8. DATE OF REVISION OF THE TEXT</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                12/2022
            </div>
        </div>
    </div>
</div>

            }    </div>
    <div id="f-div" class="box-data">
        
<div class="row clearfix rtl">
    <div class="container-fluid">
        <!-- Basic Example -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>صورة المنتج على الرف</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic" data-slide-to="0" class="active"></li>
                        <li data-target="#carousel-example-generic" data-slide-to="1" class=""></li>
                        <li data-target="#carousel-example-generic" data-slide-to="2" class=""></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                            
                                <img src="/images/nodrugimags.png">
                        </div>

                    </div>

                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# Basic Example -->
        <!-- With Captions -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>الصورة الاساسية</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic_2" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic_2" data-slide-to="0" class=""></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="1" class="active"></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="2"></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                                <img src="/images/nodrugimags.png">
                        </div>
                    </div>
                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic_2" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic_2" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# With Captions -->
    </div>
</div>


    </div>

    <!-- #END# Tabs With Custom Animations -->
</div>
        <a style="background-image: url('../images/banner.png');"
           class="scroll-top">
            <img style="margin: 15px;" src="/images/icons/up-arrow2.png" width="35">
        </a>

        <div class="footer navbar-fixed-bottom">
            <small style="color: white; margin-left: 30px;">All Rights Reserved - SFDA &copy; 2020</small>
            <br class="visible-xs visible-sm"><br class="visible-xs visible-sm">

        </div>
    </section>


    <script src="/lib/json2/json2.js?v=w3DjWhUtDqy3bSJKv285C-2kagUtW9F64T9z3xRah8g"></script>
    <script src="/lib/jquery/dist/jquery.js?v=w4hyv6-vmv08RC2hK00wXgxDziKII9paMAbU_M-5dgY"></script>
    <script src="/lib/bootstrap/dist/js/bootstrap.js?v=T574NvJTWc-Pan8hAmnXXc0eZFiqKRp7xQ3sz5QiFOk"></script>
    <script src="/lib/moment/min/moment-with-locales.js?v=5f0RFtuChrGi6osDzegxXWf5yOkmx45i7J9fM1p6P5w"></script>
    <script src="/lib/jquery-validation/dist/jquery.validate.js?v=ZDzsHzuLAtqQVxXwbgRtfAPXQ7UAoJRXBAUDvc9G9CI"></script>
    <script src="/lib/blockUI/jquery.blockUI.js?v=KKcUNqwNyTLaXzvuMyFk6JisiQq6Hk7ZtrciXnEf3Z0"></script>
    <script src="/lib/toastr/toastr.js?v=s1ewxfN8Vn23TAVRLUk8XiQUAw6uWhhuPO9dmtYzUiA"></script>
    <script src="/lib/sweetalert/dist/sweetalert.min.js?v=aPktydUv1rN3mouQeXoKi3ioFTIQlULuqYeoTAA2ihY"></script>
    <script src="/lib/spin.js/spin.js?v=b1plKpQIB-XuGyjWec42MhmhpPzEPzFI3OC8Ia0XIoc"></script>
    <script src="/lib/spin.js/jquery.spin.js?v=i7H7HL08ldqUANgfQInE7LlU2uWUdQMCJ-Q7-_zLutY"></script>
    <script src="/lib/bootstrap-select/dist/js/bootstrap-select.js?v=tXulJKckrq2j2wo8a9hvmXLDEQwhGviPTIYmEzy1dNI"></script>
    <script src="/lib/jquery-slimscroll/jquery.slimscroll.js?v=ESVSX4dkOxamaRoYfcqPM2FfErhgfxS60fp1Fa8ou1w"></script>
    <script src="/lib/Waves/dist/waves.js?v=ZOMv1vwqpT_ezNZGhvr9jJTr_jqu3lYHB7vmpxD7HmA"></script>
    <script src="/lib/push.js/push.js?v=w347yqiscLjM_TxUKpqeUA1LDR3w5vshQpxpTsgkLhE"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/abp.js?v=EjNSmvtPSqCVK_xG_aTvOp8hmVM_7vwyd3hg45CAMGk"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.jquery.js?v=XEXcdRYb4eN3XoQCbnM-BSR6UifHRLsXYDIVFZ7Oc6Q"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.toastr.js?v=h3viOCmHM1K7HnYUuJPDvLchk2Ge8CoKvl6ZJfICgII"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.blockUI.js?v=vMuHbqHh635SKL2RG2qsGGCDyHg1yFeGqhPKpS34g4k"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.spin.js?v=djoKib6ssm5DDzbXLe5pD7ayfFg3siaoEk-BFYzQlvI"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.sweet-alert.js?v=fPp3O_ILaqD0UHiR721w1i4iBtxo3NH7yfldI5dg0_I"></script>
    <script src="/js/admin.js?v=nakObLuf3yPs2VlWrIris5w-48c36X3YIRrxIis7IKQ"></script>
    <script src="/js/main.js?v=x_HDlXByl0okIi4i04d4Q_fNr85GPQi1W8gjs82s-n8"></script>
    <script src="/view-resources/Views/Shared/_Layout.js?v=36YkLzPJaGejZMB10f2T6f1rMVIzDKq96kjfcnxcLVg"></script>


        <script src="/lib/jquery-validation/src/localization/messages_ar.js?v=6kzy-p-PtvkHPWdHWyjMOIfwhBFlUYYv9jnF7zJnpUI"></script>

    <!-- Dynamic scripts of ABP system (They are created on runtime and can not be bundled) -->
    <script src="/AbpServiceProxies/GetAll?v=638865394571695575" type="text/javascript"></script>
    <script src="/AbpScripts/GetScripts?v=638865394571695575" type="text/javascript"></script>
    <script src="/lib/signalr-client/signalr.min.js?v=1yGr-J4NjYMQVt6LP6vocjHIWhO-BFQLfdCs8x1Mv-U"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.signalr-client.js?v=jTdZBAadu6DXq0iDTFX6vsn4q6bFhKm3XfN8Jz6dSmg"></script>
    
    <!-- View specific scripts -->
    
    <script src="/view-resources/Views/Home/Index.js?v=mAIakROmG_IlahImCtfrMSdaLPTG5Uoh6Z0hM1g3cxw"></script>
    <script src="/view-resources/Views/Home/Result.js?v=0pEgOuTQc8ZyJaaOpJCG7ytkKSCkzEMYCHEJfKDWu4k"></script>
    <script src="/view-resources/Views/Home/DrugsSearch.js?v=04aRniTG_ClH5tABzf7EDwQgWVpkDNpjeJUDSGvOK_Y"></script>

</body>
</html>